Zobrazeno 1 - 10
of 85
pro vyhledávání: '"Hong Liu‐Seifert"'
Publikováno v:
Patient Preference and Adherence, Vol 2010, Iss default, Pp 369-377 (2010)
Hong Liu-Seifert1, Olawale O Osuntokun1, Jenna L Godfrey2, Peter D Feldman11Lilly Research Laboratories, Indianapolis, IN, USA; 2Durham Veterans Affairs Medical Center, Durham, NC, USAAbstract: This analysis examined patient-reported attitudes toward
Externí odkaz:
https://doaj.org/article/1a2f1439c2ba4ea9ba9e243c8416dcad
Publikováno v:
Patient Preference and Adherence, Vol 2010, Iss default, Pp 11-16 (2010)
Hong Liu-Seifert, Shuyu Zhang, Deborah D’Souza, Vladimir SkljarevskiLilly Research Laboratories, Indianapolis, IN, USAPurpose: The baseline-observation-carried-forward (BOCF) approach is one method to handle missing data from early treatment discon
Externí odkaz:
https://doaj.org/article/fe31320a55fb4b94bcf846c31d31dd07
Publikováno v:
Neuropsychiatric Disease and Treatment, Vol 2009, Iss default, Pp 47-54 (2009)
Hong Liu-Seifert1, Bruce J Kinon1, Christopher J Tennant2, Jennifer Sniadecki1, Jan Volavka31Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA; 2CJT Biomedical Consulting, South Lake Tahoe, CA, USA; 3Ne
Externí odkaz:
https://doaj.org/article/f8f07dff813c429bb02e706763cc4764
Publikováno v:
Patient Preference and Adherence, Vol 2009, Iss default, Pp 31-43 (2009)
Eric Nantz1, Hong Liu-Seifert2, Vladimir Skljarevski21Department of Statistics, Western Michigan University, Kalamazoo, MI, USA; 2Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USABackground: Premature discontinuation of treatm
Externí odkaz:
https://doaj.org/article/adba965328fd478797c0f47e46aeff90
Publikováno v:
PLoS ONE, Vol 10, Iss 3, p e0119632 (2015)
One method for demonstrating disease modification is a delayed-start design, consisting of a placebo-controlled period followed by a delayed-start period wherein all patients receive active treatment. To address methodological issues in previous dela
Externí odkaz:
https://doaj.org/article/289605412a574e48872b12c4d00111bf
Autor:
Fabian Model, Michael C. Donohue, Nicola Volye, Alzheimer’s Disease Neuroimaging Initiative, Michael S. Rafii, Paul S. Aisen, Paul Delmar, Hong Liu-Seifert
Publikováno v:
Alzheimers Dement
In clinical trials in populations with mild cognitive impairment, it is common for participants to initiate concurrent symptomatic medications for Alzheimer's disease after randomization to the experimental therapy. One strategy for addressing this o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da65670746acbf0d5aa1c0f967809872
https://doi.org/10.1002/alz.12058
https://doi.org/10.1002/alz.12058
Autor:
Soyi Liu Leage, Hong Liu-Seifert, Melinda Gooderham, Frank Behrens, Hasan Tahir, Philip S. Helliwell, Josef S Smolen, Eswar Krishnan, Lingnan Li, Philip J. Mease, Peter Nash, Paul Emery, Sreekumar G. Pillai
Publikováno v:
Annals of the Rheumatic Diseases
ObjectivesTo compare efficacy and safety of ixekizumab (IXE) to adalimumab (ADA) in biological disease-modifying antirheumatic drug-naïve patients with both active psoriatic arthritis (PsA) and skin disease and inadequate response to conventional sy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7114ab18d79973859be70a433c9313e
https://doi.org/10.1136/annrheumdis-2019-215386
https://doi.org/10.1136/annrheumdis-2019-215386
Autor:
Eric Siemers, Suzanne Hendrix, Alette M. Wessels, JonDavid Sparks, Michael Case, Paul S. Aisen, Scott W. Andersen, Hong Liu-Seifert, Karen C. Holdridge
Publikováno v:
Journal of Biopharmaceutical Statistics. 27:1104-1114
Little research has been conducted on the statistical properties of composite measures comprising linear combinations of continuous component scales. We assessed the quantitative relationship between the composites and their individual components reg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca9630b3d68fbcd473956f459d8fb53c
https://doi.org/10.1080/10543406.2017.1315819
https://doi.org/10.1080/10543406.2017.1315819
Autor:
David Henley, Ann Marie Hake, Hong Liu-Seifert, Kristin Kahle-Wrobleski, Eric Siemers, Yun Fei Chen, Wenyu Ye
Publikováno v:
Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring
Introduction Characterization of the quality of life (QOL) in Alzheimer's disease (AD) scale within the context of a clinical trial may inform its applicability in future trials. Methods Using data from 1322 patients enrolled in two phase-III studies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0be7244874e554258f8290e56b9f686e
https://doi.org/10.1016/j.dadm.2016.11.004
https://doi.org/10.1016/j.dadm.2016.11.004
Autor:
Wen Li, Scott W. Andersen, Steve Wilson, Richard Entsuah, Hong Liu-Seifert, Ying Tian, Jennifer Schumi, Xiaopeng Miao, Michael Rabbia
Publikováno v:
Therapeutic innovationregulatory science. 54(2)
Alzheimer’s disease (AD) has increasingly been recognized as a huge unmet medical need. Currently, there is no approved drug to cure, prevent, or even slow down the disease. It is imperative to develop disease-modifying treatments for AD to alter t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b982f013196682ceba041d94b5c061ce
https://pubmed.ncbi.nlm.nih.gov/32072596
https://pubmed.ncbi.nlm.nih.gov/32072596